LAMP2 and Pleural effusion: Glycoproteomics studies, performed by different methods for glycoprotein fractionation (multilectin chromatography or N-GP capture) followed by LC-MS/MS, revealed potential lung cancer biomarkers, such as plasma kallikrein (KLKB1) [29], pleural effusion periostin, multimerin-2, CD166, and lysosome-associated membrane glycoprotein-2 (LAMP-2) [30].